“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in SEK
Last close As at 09/06/2023
SEK4.64
▲ 0.03 (0.65%)
Market capitalisation
SEK775m
Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.
Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.
Managing Director - Head of Content, Healthcare
Goran Forsberg
CEO
Forecast net cash (SEKm)
119.4
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | (21.0) | (29.4) | (67.7) |
| Relative | (21.7) | (29.5) | (68.5) |
| 52 week high/low | SEK14.1/SEK3.0 |
Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial, investigating nadunolimab in first-line NSCLC and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy. The company is now preparing for a Phase II/III trial in metastatic PDAC in collaboration with PanCAN and a follow-on randomised study in NSCLC. Additionally, in Q123, the first patient was dosed in the Phase II part of the TRIFOUR study investigating nadunolimab for the treatment of triple-negative breast cancer. A second programme, CAN10, is being developed for the treatment of myocarditis and systemic sclerosis and the company intends to initiate Phase I trials in H123. Cantargia had a cash and short-term investment position of SEK426.7m at end-FY22.
| Y/E Dec | Revenue (SEKm) | EBITDA (SEKm) | PBT (SEKm) | EPS (öre) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.0 | (366.8) | (366.5) | (365.80) | N/A | N/A |
| 2022A | 0.0 | (377.9) | (371.8) | (290.43) | N/A | N/A |
| 2023E | 0.0 | (302.1) | (306.6) | (183.58) | N/A | N/A |
| 2024E | 0.0 | (286.9) | (292.6) | (175.20) | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
